NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Core Viewpoint - NeoGenomics, Inc. will report its fourth quarter and full year 2025 financial results on February 17, 2026, prior to the U.S. market opening, with a subsequent webcast and conference call scheduled for discussion [1]. Company Overview - NeoGenomics, Inc. is a leading cancer diagnostics company that specializes in cancer genetics testing and information services, providing a comprehensive oncology-focused testing menu [3]. - The company serves a variety of clients including oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms, offering innovative diagnostic and predictive testing to aid in cancer diagnosis and treatment [3]. - Headquartered in Fort Myers, Florida, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories across the U.S. and a CAP-accredited laboratory in Cambridge, United Kingdom [3].